Table 4.

Summary of the COMBI-d efficacy results along with the reported dermatologic adverse events^a.

Study group		Dabrafenib plus trametinib	Dabrafenib
Overall survival
	Value, median (months)	25.1	18.7
	HRb	0.71c	N/Ad
Progression-free survival
	Value, median (months)	11.0	8.8
	HR	0.67c	N/A
Adverse events (all grade), %		87	90
Adverse events (grade ≥3), %		32	30
Dermatologic adverse events
	Rash (all grade), %	24	20
	Rash (grade ≥3), %	0	<1
	Dry skin (all grade), %	9	14
	Dry skin (grade ≥3), %	0	0
	Pruritus (all grade), %	7	11
	Pruritus (grade ≥3), %	0	0
	Alopecia (all grade), %	5	26
	Alopecia (grade ≥3), %	0	0
	Hyperkeratosis (all grade), %	6	33
	Hyperkeratosis (grade ≥3), %	0	<1
	Skin papilloma (all grade), %	1	18
	Skin papilloma (grade ≥3), %	0	0
	Dermatitis acneiform (all grade), %	8	3
	Dermatitis acneiform (grade ≥3), %	0	0
	Squamous cell carcinoma (all grade), %	3	9
	Squamous cell carcinoma (grade ≥3), %	3	9
	New primary melanoma (all grade), %	<1	2
	New primary melanoma (grade ≥3), %	<1	<1

^aAdapted from Long et al [14].

^bHR: hazard ratio.

^cDabrafenib plus trametinib versus trametinib.

^dN/A: not applicable.